Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Novadaq (NASDAQ: NVDQ) and Neurocrine (NASDAQ: NBIX)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (NASDAQ: ALNY), Novadaq (NASDAQ: NVDQ) and Neurocrine (NASDAQ: NBIX) with bullish sentiments.

Alnylam Pharma (NASDAQ: ALNY)

In a report released today, Ritu Baral from Cowen & Co. reiterated a Buy rating on Alnylam Pharma (NASDAQ: ALNY), with a price target of $100. The company’s shares opened today at $31.41, close to its 52-week low of $31.38.

Baral commented:

“ALNY gave incremental additional detail on the revusiran safety events that led to.”

According to TipRanks.com, Baral is a 2-star analyst with an average return of -0.3% and a 31.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on Alnylam Pharma is Moderate Buy and the average price target is $65.25, representing a 107.7% upside.

In a report issued on October 24, Piper Jaffray also reiterated a Buy rating on the stock with a $106 price target.
Novadaq (NASDAQ: NVDQ)

In a report released yesterday, Jason Mills from Canaccord Genuity reiterated a Buy rating on Novadaq (NASDAQ: NVDQ), with a price target of $15. The company’s shares opened today at $9.14, close to its 52-week low of $8.26.

According to TipRanks.com, Mills is a 1-star analyst with an average return of -1.3% and a 51.2% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.

Novadaq has an analyst consensus of Strong Buy, with a price target consensus of $17.

Neurocrine (NASDAQ: NBIX)

Cowen & Co. analyst Phil Nadeau reiterated a Buy rating on Neurocrine (NASDAQ: NBIX) yesterday and set a price target of $65. The company’s shares opened today at $40.16.

Nadeau commented:

“NBIX remains well funded, ending Q3 with $385MM in cash and equivalents.”

According to TipRanks.com, Nadeau is a 1-star analyst with an average return of -3.1% and a 34.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Neurocrine is Strong Buy and the average price target is $64.67, representing a 61.0% upside.

In a report issued on October 18, Piper Jaffray also reiterated a Buy rating on the stock with a $96 price target.